Abstract:Abstract Background: Tumors often demonstrate initial responses to cisplatin-based chemotherapy in treating non-small cell lung cancer (NSCLC), but eventually develop resistance and limit the success of therapy. We investigated whether IL-6 signaling is important in developing cisplatin-resistance of NSCLC and explore if targeting IL-6 signaling may increase tumor sensitivity to cisplatin. Methods: We performed in vitro cytotoxicity test using the IL-6 knocked down and scramble (sc) control A549 and H157 NSCLC cell lines (A549IL-6si/sc and H157IL-6si/sc). We also performed in vivo mice studies by establishing xenografts using the A549IL-6si/sc cell set. We next examined the mechanism by which IL-6 mediates cisplatin resistance by performing studies of qPCR, Western analyses, and applying inhibitors of intracellular signaling molecules. Finally, we independently developed the cisplatin resistant A549 (A549CisR) and H157(H157CisR) cell lines and investigated whether targeting IL-6 signaling using a neutralizing antibody of IL-6 could prime these cicplatin-resistant cells to increase the sensitivity to cisplatin. Results: The in vitro survival tests revealed that cisplatin was more cytotoxic to the IL-6 knocked down A549IL-6si and H157IL-6si cells than sc control cells. In in vivo mice studies, we consistently observed more effective tumor regression in A549IL-6si cells-derived xenografts than sc cells-derived tumors (control) after cisplatin treatments. In mechanistic studies, we found that expressions of the anti-apoptotic proteins (Bcl-2 and Mcl-1) and the molecules associated with DNA repair (ATM, CHK1, TP73, p53, and ERCC1) were significantly increased upon cisplatin treatment in A549sc and H157sc cells, but not in IL-6si cells of A549 and H157. The molecular inhibitor studies further revealed that the activation of signaling pathways, such as Stat3, Akt, MAPK, and Erk, was responsible for the up-regulation of these molecules. Further, when we treated cisplatin resistant-A549 and H157 cell lines (A549CisR and H157CisR) with a neutralizing antibody of IL-6, we observed increased cell cytotoxicity. Conclusions and Impact: Our data support that the IL-6 signaling may be critical in conferring NSCLC cell resistance to cisplatin. In addition, we demonstrated that targeting IL-6 signaling could overcome the established acquired cisplatin resistance. Our observation supports a possible strategy to overcome cisplatin resistance through targeting IL-6 signaling or its downstream molecule(s) in treating NSCLC. Citation Format: Shan-zhou Duan, Ying Tsai, Peter Keng, Yongbing Chen, Soo Ok Lee, Yuhchyau Chen. IL-6 signaling modulates cisplatin resistance in non-small cell lung cancer via up-regulations of anti-apoptotic and DNA repair associated molecules. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 740. doi:10.1158/1538-7445.AM2015-740

Abstract 2568: Acquired Apoptosis Resistance Mediated by Activation of the Akt/COX-2/Mcl-1 Pathway in Lung Cancer Cells

Acquired Activation of the Akt/Cyclooxygenase-2/Mcl-1 Pathway Renders Lung Cancer Cells Resistant to Apoptosis

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

Akt-Mediated Eminent Expression of C-Flip and Mcl-1 Confers Acquired Resistance to Trail-Induced Cytotoxicity to Lung Cancer Cells

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

BIM Induction of Apoptosis Triggered by EGFR-sensitive and Resistance Cell Lines of Non-Small-cell Lung Cancer

Synergy Between Phosphatidylinositol 3-Kinase/akt Pathway and Bcl-xL in the Control of Apoptosis in Adenocarcinoma Cells of the Lung.

Abstract 415: Metabolic reprogramming driven by IGF2BP3-COX6B2 axis promotes acquired resistance to EGFR-TKIs in non-small lung cancer

Simultaneous Targeting of ATM and Mcl-1 Increases Cisplatin Sensitivity of Cisplatin-Resistant Non-Small Cell Lung Cancer

Abstract 1088: Acquired radiation resistance induces thiol-dependent cisplatin cross-resistance

lncCRLA Enhanced&nbsp;Chemoresistance in Lung Adenocarcinoma That Underwentepithelial-mesenchymal Transition

Absence of Death Receptor Translocation into Lipid Rafts in Acquired TRAIL-resistant NSCLC Cells.

Abstract 5826: Comprehensive analysis with single-cell RNA sequence and spatial transcriptomics unravels distinctive expression profile of apoptotic-related genes in EGFR-mutated lung cancer

Abstract 2338: EGFR-mediated TGM2 Overexpression Couples Acquired TRAIL-resistance and Migration Involving C-Flip and MMP9 in NSCLC Cells

Lnccrla Enhanced Chemoresistance in Lung Adenocarcinoma That Underwentepithelial-mesenchymal Transition

Abstract 740: IL-6 Signaling Modulates Cisplatin Resistance in Non-Small Cell Lung Cancer Via Up-Regulations of Anti-Apoptotic and DNA Repair Associated Molecules

Akt-Mediated Cisplatin Resistance in Ovarian Cancer: Modulation of p53 Action on Caspase-Dependent Mitochondrial Death Pathway

Abstract #5510: Molecular Mechanism of Tamoxifen Therapy for Cholangiocarcinoma

MCL-1 is the Key Target of Adjuvant Chemotherapy to Reverse the Cisplatin-Resistance in NSCLC.

Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.